Prealbumin (PA) e l e c t r o p h o r e t i c a l l y precedes t h e plasma p r o t e i n albumin. Unlike albumin. i t h a s a s h o r t h a l f l i f e ---
(1.9 d a y s ) and t h e r e f o r e , may s e r v e a s a r e l i a b l e index of n u t r i t i o n a l s t a t u s . T h i s would be p a r t i c u l a r l y u s e f u l i n d i s t i n g u i s h i n g s m a l l f o r g e s t a t i o n a l age (SGA) neonates secondary t o f e t a l m a l n u t r i t i o n from t h o s e whose weight i s c o n s t i t u t i o n a l l y low f o l l o w i n g normal i n t r a u t e r i n e n u t r i t i o n .
T h e r e f o r e , plasma PA Levels were measured i n t h e cord blood of 175 n e o n a t e s g e s t a t i o n a l a g e s (GA) 33-42 weeks u s i n g a s o l i d phase enzyme imnunoassay. B i r t h w e i g h t p e r c e n t i l e s f o r t h e s e n e o n a t e s i n d i c a t e 16 were l a r g e f o r g e s t a t i o n a l age (LGA) 2 9 0 t h . 10 were s m a l l f o r g e s t a t i o n a l a g e < l o t h , and 149 were a p p r o p r i a t e f o r g e s t a t i o n a l age (AGA) 11-89th p e r c e n t i l e .
P r e t e m n e o n a t e s (n=32, mean t SD, G A 3 6 t 1 wk) had a s i g n i f ic a n t l y ( p < .003) lower PA mean l e v e l (8.6 mgldl) t h a n term (10.4 mg/dl) n e o n a t e s (n=143. meantSD, G A 40+1 wk) b u t t h e r e was not a s i g n i f i c a n t c o r r e l a t i o n ( r = . l , p >.35) between GA, b i r t h w e i g h t o r grawth p e r c e n t i l e s and plasma PA l e v e l s . S i m i l a r l y , t h e mean PA f o r SGA, LGA and AGA n e o n a t e s d i d n o t d i f f e r s i g n i f i c a n t l y . These d a t a i n d i c a t e t h a t prealbumin i s not a r e l i a b l e index of F e t a l n u t r i t i o n . 
PROSPECTIVE EVALUATION OF RANITIDINE (R) IN PEDIAT-

RIC ULCER DISEASE (PUD
PUD) i s no longer a r a r e problem. Despite various claims f o r e f f i c a c y , t h e r e a r e few o b j e c t i v e data a v a i l a b l e t o support any treatment regimens f o r PUD. We a r e p r o s p e c t i v e l y e v a l u f k j n g t h e s a f e t y , pharmacokinetics and t h e r a p e u t i c e f f i c a c y o f R , a new
Hz antagonist i n t h e treatment o f PUD. Nine c h i l d r e n (C) (3.5-
6.5yrs) who presented w i t h complaints o f e p i g a s t r i c pain (8),
vomiting ( 8 ) , nausea (7), hematemesis (3) and melena (1) have been studied. S i x C had c h r o n i c complaints ( > 3 wks) and 2 C had a hx o f r e c e n t ASA use. A l l C (5M:4F) had endoscopically proven u l c e r s ( 5 g a s t r i c , 2 p y l o r i c , 2 duodenal). Therapy was designed t o achieve g a s t r i c a c i d suppression and u l c e r healing. A f t e r basal a c i d o u t p u t (BAO) was determined a R i n f u s i o n was given t o achieve 90% suppression o f BAO. I n d i v i d u a l pharmacokinetics were determined and an e f f e c t i v e serum concentration 22.6 ng/ml (9-65 ng/ml) was r e q u i r e d t o achieve 90% suppression. Once C were e a t i n g and placed on o r a l R, dosage was adjusted t o account f o r i n d i v i d u a l d i f f e r e n c e s i n b i o a v a i l a b i l i t y . Weekly followup r evealed no c l i n i c a l , biochemical, h e p a t i c o r renal abnormalities. E i g h t C were asymptomatic w i t h i n t h e f i r s t 3 wks o f R therapy. One c h i l d has shown steady symptomatic improvement b u t nausea p e r s i s t s . Complete u l c e r h e a l i n g has been endoscopically documented a f t e r 6 wks o f therapy. An o r a l dose o f 0.5 mg/kg q 12h i s e f f e c t i v e i n h e a l i n g u l c e r s h e a l i n g i n C. R appears t o be a safe and e f f e c t i v e drug f o r t h e treatment o f PUD. 
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I n t r a c t a b l e d i a r r h e a of i n f a n c y i s a heterogeneous group of d i s o r d e r s r e s u l t i n g i n p r o t r a c t e d d i a r r h e a .
Secondary c a r b o h y d r a t e i n t o l e r a n c e p l a y s an i m p o r t a n t r o l e i n t h i s r e g a r d . These a r e u s u a l l y r e l a t e d t o l a ct a s e and s u c r a s e d e f i c i e n c y . More r e c e n t l y , glucoamyl a s e d e f i c i e n c y h a s been d e s c r i b e d . I n a l l of t h e above i n s t a n c e s , a marked e n t e r i t i s was p r e s e n t . W e r e p o r t 2 p a t i e n t s who c o n t i n u e d t o have d i a r r h e a , w i t h p o s i t i v e reducing s u b s t a n c e s i n t h e s t o o l , w h i l e on d i e t s w i t h g l u c o s e polymers a s t h e s o l e CHO s o u r c e . These p a t i e n t s aged 4 & 9 months, p r e s e n t e d w i t h d i a r r h e a of 1 and 4 months d u r a t i o n . J e j u n a l b i o p s i e s were normal under l i g h t microscopy and on EM. D e s p i t e minimal morphologi c a l changes, b o t h p a t i e n t s had a marked d e c r e a s e i n l a c t a s e , s u c r a s e , m a l t a s e , and glucoamylase a c t i v i t y i n j e j u n a l biopsy specimens. Duodenal f l u i d , amylase, and t r y p s i n were normal. Formulae (RCF & 3232A3, w i t h g l u c o s e monosaccharide a s t h e CHO s o u r c e , a l l e v i a t e d t h e d i a r r h e a . Conclusions: 1. Glucoamylase d e f i c i e n c y i s a s i g n i f i c a n t c l i n i c a l e n t i t y and i s i m p o r t a n t i n p e r p e t u a t i n g d i a r r h e a i n t h e s e p a t i e n t s . 2. L i g h t microscopy of s m a l l i n t e s t i n a l biopsy may b e normal. 3. Formulae c o n t a i n i n g g l u c o s e and f r u c t o s e monosacchari d e s a s t h e CHO s o u r c e a l l e v i a t e t h e d i a r r h e a . 12 k A 28-32'week gestation infants were studied k i n g the f i r s t 2-3 mss. of l i f e t o detemuhe the effect of feeding premture hman milk (HM), fortified premature hunm milk (RIM) and Sinilac Special Care (SSC) 
